Pooled week 48 safety and efficacy results from the ECHO and THRIVE phase III trials comparing TMC278 vs EFV in treatment-naïve, HIV-1-infected patients

por Cohen, C, Molina, JM, Cahn, P, Clotet, B, Fourie, J, Grinsztejn, B, Hao, W, Johnson, M, Supparatpinyo, K, Crauwels, HM, Rimsky, L, Vanveggel, S, Williams, P, Boven, K
Publicado 2010